A Rare Case of Pembrolizumab-Induced Uveitis in a Patient with Metastatic Melanoma

Pharmacotherapy

Volumn 36, Issue 11, 2016, Pages e183-e188

  Hanna, Kirollos S ^a  

^a MAYO CLINIC   (United States)

Author keywords

adverse events; autoimmune complications; drug associated uveitis; melanoma; pembrolizumab

Indexed keywords

ACETYLSALICYLIC ACID; B RAF KINASE; B RAF KINASE INHIBITOR; LACTATE DEHYDROGENASE; METHYLPREDNISOLONE; ONDANSETRON; PEMBROLIZUMAB; PREDNISONE; PROGRAMMED DEATH 1 RECEPTOR; STEROID; TRIAMCINOLONE; ANTINEOPLASTIC AGENT; CORTICOSTEROID; MONOCLONAL ANTIBODY; PDCD1 PROTEIN, HUMAN;

ADVERSE OUTCOME; AGED; ARTICLE; ATAXIA; AUTOIMMUNE DISEASE; BILATERAL HEARING LOSS; BLURRED VISION; BRAF GENE; BRAIN INFARCTION; CANCER CELL; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER PATIENT; CANCER RECURRENCE; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; DRUG APPROVAL; DRUG MEGADOSE; DRUG WITHDRAWAL; EYE INFLAMMATION; EYE INJURY; FEMALE; FOOD AND DRUG ADMINISTRATION; GENE MUTATION; HEARING DISORDER; HEARING TEST; HUMAN; IMMUNE RESPONSE; INCIDENCE; LENS DISEASE; LIVER METASTASIS; MEDICAL HISTORY; METASTATIC MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR SCLEROSIS; OUTCOME ASSESSMENT; PATIENT SAFETY; PIGMENTATION; RARE DISEASE; SLIT LAMP; SUBCAPSULAR CATARACT; SUPRACLAVICULAR LYMPH NODE; T LYMPHOCYTE; UVEITIS; VESTIBULAR HYPOFUNCTION; VISUAL IMPAIRMENT; ANTAGONISTS AND INHIBITORS; CHEMICALLY INDUCED; MELANOMA; PATHOLOGY; SKIN NEOPLASMS;

ADRENAL CORTEX HORMONES; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; FEMALE; HUMANS; MELANOMA; PANUVEITIS; PROGRAMMED CELL DEATH 1 RECEPTOR; SKIN NEOPLASMS;

EID: 84995743532     PISSN: 02770008     EISSN: 18759114     Source Type: Journal    
DOI: 10.1002/phar.1839     Document Type: Article

References (27)

1. Durrani OM, Tehrani NN, Marr JE, Moradi P, Stavrou P, Murray PI. Degree, duration, and causes of visual loss in uveitis. Br J Ophthalmol 2004;88(9):1159–62.
2. Naidoo J, Page DB, Li BT, et al. Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol 2015;26(12):2375–91.
3. Champiat S, Lambotte O, Barreau E, et al. Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper. Ann Oncol 2016;27(4):559–74.
4. Hamid O, Robert C, Daud A, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med 2013;369(2):134–44.
5. Ribas A, Hodi FS, Kefford R, et al. Efficacy and safety of the anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) in 411 patients (pts) with melanoma (MEL). J Clin Oncol 2014;32:5s (suppl.; abstr LBA9000^).
6. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet 2014;384(9948):1109–17.
7. Duad A, Ribas A, Robert C, et al. Long-term efficacy of pembrolizumab (pembro; MK-3475) in a pooled analysis of 655 patients (pts) with advanced melanoma (MEL) enrolled in KEYNOTE-001. J Clin Oncol 2015;33 (suppl.; abstr 9005).
8. Ribas A, Hamid O, Daud A, et al. Association of pembrolizumab with tumor response and survival among patients with advanced melanoma. JAMA 2016;315(15):1600–9.
9. Topalian SL, Hodi FS, Brahmer JR, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012;366(26):2443–54.
10. Weber JS, Kähler KC, Hauschild A. Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 2012;30(21):2691–7.
11. Martin-liberal J, Kordbacheh T, Larkin J. Safety of pembrolizumab for the treatment of melanoma. Expert Opin Drug Saf 2015;14(6):957–64.
12. Alabed YZ, Aghayev A, Sakellis C, Van den Abbeele AD. Pancreatitis secondary to anti-programmed death receptor 1 immunotherapy diagnosed by FDG PET/CT. Clin Nucl Med 2015;40(11):e528–9.
13. Abu Samra K, Valdes-navarro M, Lee S, Swan R, Foster CS, Anesi SD. A case of bilateral uveitis and papillitis in a patient treated with pembrolizumab. Eur J Ophthalmol 2016;26(3):e46–8.
14. Taylor S, Hrisomalos F, Linette G, et al. A case of recurrent bilateral uveitis independently associated with dabrafenib and pembrolizumab therapy. AJO Case Reports 2016;2:23–5.
15. Basilious A, Lloyd JC. Posterior subcapsular cataracts and hypotony secondary to severe pembrolizumab induced uveitis: case report. Can J Ophthalmol 2016;51(1):e4–6.
16. Min L, Hodi FS, Kaiser UB. Corticosteroids and immune checkpoint blockade. Aging (Albany, NY) 2015;7(8):521–2.
17. Dolan DE, Gupta S. PD-1 pathway inhibitors: changing the landscape of cancer immunotherapy. Cancer Control 2014;21(3):231–7.
18. Brahmer JR, Tykodi SS, Chow LQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med 2012;366(26):2455–65.
19. Lexi-Comp, Inc. Lexi-Drugs package insert. Lexi-Comp, Inc.; 2016.
20. Sheppard JD, Toyos MM, Kempen JH, Kaur P, Foster CS. Difluprednate 0.05% versus prednisolone acetate 1% for endogenous anterior uveitis: a phase III, multicenter, randomized study. Invest Ophthalmol Vis Sci 2014;55(5):2993–3002.
21. Joshi L, Talat L, Yaganti S, et al. Outcomes of changing immunosuppressive therapy after treatment failure in patients with noninfectious uveitis. Ophthalmology 2014;121(5):1119–24.
22. De velasco G, Bermas B, Choueiri TK. Autoimmune arthropathy and uveitis as complications of programmed death 1 inhibitor treatment. Arthritis Rheumatol 2016;68(2):556–7.
23. Miserocchi E, Cimminiello C, Mazzola M, Russo V, Modorati GM. New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient. Can J Ophthalmol 2015;50(1):e2–4.
24. Hahn L, Pepple KL. Bilateral neuroretinitis and anterior uveitis following ipilimumab treatment for metastatic melanoma. J Ophthalmic Inflamm Infect 2016;6(1):14.
25. Chen L, Pai V, Levinson R, et al. Constitutive neuronal expression of the immune regulator, programmed death 1 (PD-1), identified during experimental autoimmune uveitis. Ocul Immunol Inflamm 2009;17(1):47–55.
26. Yang W, Li H, Chen PW, et al. PD-L1 expression on human ocular cells and its possible role in regulating immune-mediated ocular inflammation. Invest Ophthalmol Vis Sci 2009;50(1):273–80.
27. Naranjo CA, Busto U, Sellers EM, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30(2):239–45.